Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Setting the Stage to Find Drugs Against SARS

21.11.2006
Scientists at the U.S. Department of Energy’s Brookhaven National Laboratory have set the stage for the rapid identification of compounds to fight against severe acquired respiratory syndrome (SARS), the atypical pneumonia responsible for about 800 deaths worldwide since first recognized in late 2002.

Researchers from Brookhaven’s biology department and the National Synchrotron Light Source (NSLS) characterized a component of the virus that will be the target of new anti-SARS virus drugs. The results were published online by Biochemistry on November 17, 2006.

“Although vaccines against viruses are very effective, vaccines for viruses that mutate rapidly – such as the viruses that cause SARS, AIDS, and bird flu – are much more difficult to obtain,” said Brookhaven biologist Walter Mangel, the lead author of the paper. “Even if a vaccine is available, antiviral agents are important in stopping the spread of highly infectious viruses. If antiviral agents for SARS had been available, they could have been used to contain the outbreak to the initial site of the infection.”

The researchers studied the SARS main proteinase, an enzyme used by the virus during infection to cut newly made viral proteins into gene-sized, functioning pieces. If the proteinase is prevented from working, the virus infection is aborted. Previous studies have revealed that the proteinase is inactive when in the form of single molecules. But once two of those molecules bind together to make what is called a dimer, the enzyme becomes active and is able to play its role in SARS virus reproduction. The challenge for researchers, and the focus of the Brookhaven study, was to determine the concentration at which individual proteinase molecules form active dimers. Knowing this concentration, for which estimates at other laboratories have varied greatly, would allow researchers to search for anti-SARS drugs more efficiently by ensuring that the proteinase used in tests is initially in its active form.

Using three different scientific techniques, including x-ray scattering at the NSLS, the Brookhaven researchers obtained almost identical values for this concentration. Now that this crucial value has been narrowed down to a precise range, researchers can focus on finding compounds that bind to the active form of the enzyme.

“Targets for antiviral drugs must be carefully chosen such that binding to it prevents the virus from reproducing,” Mangel said. “Viral proteinases are excellent targets for antiviral drugs. One reason so many people are surviving the AIDS epidemic is the effectiveness of drugs targeted to the proteinase of human immunodeficiency virus (HIV).”

One way to obtain compounds that bind to a proteinase is via high-throughput screening. Chemical libraries containing tens of thousands of small compounds are available that can be searched for effective drugs against various diseases. Small amounts of a target, e.g., an active viral proteinase, are placed in tiny wells in a plate, and a different compound from the library is added to each well.

To determine whether a compound binds to and inhibits the proteinase, an additional molecule is added that changes color in the presence of an active proteinase. Wells that don’t show a color change therefore contain compounds that inhibit the proteinase, and could be effective antiviral agents. Earlier this year, Mangel’s research group published a procedure on the synthesis of a new compound that changes color in the presence of the active form of the SARS main proteinase.

However, for this screening process to work, the SARS proteinase inserted into the wells has to be active to begin with. Knowing the concentration range for dimer formation will therefore help researchers in their search for a compound to stop the virus. “Now that the stage is set, high-throughput screening can begin,” Mangel said. “Hopefully, it will yield an antiviral agent that can be stockpiled before a virulent strain of the virus reappears.”

This research was supported by the Office of Basic Energy Sciences within the U.S. Department of Energy and the National Institutes of Health.

Karen McNulty Walsh | EurekAlert!
Further information:
http://www.bnl.gov

Further reports about: Brookhaven SARS Vaccine antiviral concentration proteinase

More articles from Life Sciences:

nachricht The birth of a new protein
20.10.2017 | University of Arizona

nachricht Building New Moss Factories
20.10.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>